In an in vivo study of pancreatic tumor cells, flow cytometric analysis revealed that IFNs can upregulate PD-L1 expression, while the expression of PD-L1 induced by IFNs can be diminished by ruxolitinib, a JAK/STAT inhibitor. This evidence concerns the gene CD274 and pancreatic neoplasm.